Jagruti C Shah, MD
Diagnostic Radiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 6
Offices
6 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shah’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C151875 · Current
Licensed to practise in California · since 2017 · expires 2027-04-30 · University of Mumbai, Topiwala National Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$105,851
Medicare paid this office $105,851 for 1,402 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Nuclear medicine study from skull base to mid-thigh with ct scan | 314 | $32,938 | $99 |
| Nuclear medicine study whole body with ct scan | 125 | $13,492 | $101 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 96 | $10,001 | $99 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 19 | $5,367 | $282 |
| Ct scan of abdomen and pelvis with contrast | 58 | $4,382 | $76 |
See all 20 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 314 | $32,938 | $99 |
| Nuclear medicine study whole body with ct scan | 125 | $13,492 | $101 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 96 | $10,001 | $99 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 19 | $5,367 | $282 |
| Ct scan of abdomen and pelvis with contrast | 58 | $4,382 | $76 |
| Nuclear medicine study whole body with ct scan | 42 | $4,266 | $99 |
| Ct scan of abdomen and pelvis with contrast | 54 | $3,900 | $71 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 59 | $3,736 | $63 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 51 | $3,096 | $56 |
| Dxa bone density measurement of hip, pelvis, spine | 256 | $2,696 | $11 |
| Radioactive drug therapy through a vein | 27 | $2,690 | $82 |
| Ct scan of chest with contrast | 47 | $2,105 | $45 |
| Dxa bone density measurement of hip, pelvis, spine | 169 | $1,776 | $11 |
| Ct scan of chest with contrast | 40 | $1,641 | $41 |
| Nuclear medicine study, spect imaging with concurrent ct scan, at least 2 areas or separate acquisitions, single day imaging, or single area or acquisition over multiple days | 14 | $1,199 | $86 |
| Nuclear medicine study of heart muscle with metabolic evaluation and concurrent ct scan | 12 | $840 | $70 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 13 | $537 | $41 |
| Nuclear medicine study of stomach to assess emptying | 18 | $534 | $30 |
| Nuclear medicine study of bone and/or joint whole body | 18 | $490 | $27 |
| Piflufolastat f-18, diagnostic, 1 millicurie | 52 | $1 | $0 |
Who their Medicare patients are
1,402 Original Medicare patients in 2024. Average age 75 · Under 65 6% · 85 and older 12% · Women 61% · Also on Medicaid 22% · Health risk score 1.95. Above the middle of the specialty; the typical diagnostic radiology clinician is at 1.7.
Conditions among them: High blood pressure 71% · Cancer 43% · Diabetes 31% · Coronary heart disease 28% · Chronic kidney disease 25% · Atrial fibrillation 21% · Depression 19% · Heart failure 17% · COPD 13% · Stroke 10% · Dementia 7%.
The office billed $3,213,110, Medicare allowed $134,957 and paid $105,851; for 1,712 services of 47 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,402 | 1,712 | 75 | 1.95 | $3,213,110 | $105,851 |
| 2023 | 1,387 | 1,737 | 74 | 1.82 | $2,045,851 | $97,215 |
| 2022 | 1,564 | 1,906 | 74 | 1.89 | $1,266,406 | $122,081 |
| 2021 | 1,414 | 6,794 | 74 | 1.61 | $1,287,262 | $328,694 |
| 2020 | 784 | 18,055 | 72 | 1.59 | $1,485,630 | $570,111 |
| 2019 | 833 | 16,232 | 72 | 1.67 | $1,479,692 | $557,532 |
| 2018 | 724 | 7,367 | 70 | 1.99 | $757,722 | $253,469 |
| 2017 | 1,061 | 1,413 | 70 | 2.20 | $533,716 | $125,076 |
| 2016 | 1,195 | 1,764 | 70 | 2.19 | $449,578 | $101,801 |
| 2015 | 965 | 1,169 | 69 | 2.16 | $312,726 | $69,526 |
| 2014 | 974 | 1,266 | 69 | 2.03 | $335,142 | $71,324 |
| 2013 | 800 | 1,039 | 69 | 1.97 | $266,680 | $53,299 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 261 | $27,086 | $100 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 95 | $10,197 | $101 |
| Nuclear medicine study whole body with ct scan | 81 | $8,449 | $101 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 81 | $5,042 | $58 |
| Radioactive drug therapy through a vein | 46 | $4,676 | $81 |
| Dxa bone density measurement of hip, pelvis, spine | 394 | $4,295 | $11 |
| Nuclear medicine study whole body with ct scan | 38 | $4,142 | $104 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 66 | $4,135 | $63 |
| Ct scan of abdomen and pelvis with contrast | 49 | $3,735 | $75 |
| Ct scan of abdomen and pelvis with contrast | 47 | $3,257 | $69 |
| Calculation of radiation therapy dose | 56 | $1,870 | $30 |
| New patient visit (60+ min) | 11 | $1,837 | $167 |
| Ct scan of chest with contrast | 40 | $1,770 | $44 |
| Ct scan of chest with contrast | 38 | $1,660 | $44 |
| Dxa bone density measurement of hip, pelvis, spine | 94 | $1,013 | $11 |
| Nuclear medicine study of bone and/or joint whole body | 25 | $912 | $35 |
| Return visit (30+ min) | 12 | $900 | $75 |
| Nuclear medicine study of lung ventilation and circulation | 15 | $645 | $43 |
| Nuclear medicine study of lymphatic system | 11 | $565 | $51 |
| Nuclear medicine study of stomach to assess emptying | 16 | $481 | $30 |
| Nuclear medicine study, whole body | 16 | $478 | $30 |
| 3d radiographic procedure with computerized image postprocessing | 12 | $422 | $35 |
| Nuclear medicine study, 1 area | 12 | $279 | $23 |
2022: 20 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 388 | $41,421 | $100 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 125 | $13,061 | $102 |
| Nuclear medicine study whole body with ct scan | 117 | $12,736 | $104 |
| Ct scan of abdomen and pelvis with contrast | 83 | $6,431 | $77 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 88 | $5,900 | $67 |
| Nuclear medicine study whole body with ct scan | 48 | $5,479 | $103 |
| Ct scan of abdomen and pelvis with contrast | 67 | $5,016 | $75 |
| Dxa bone density measurement of hip, pelvis, spine | 348 | $3,853 | $11 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 56 | $3,258 | $57 |
| Ct scan of chest with contrast | 62 | $2,937 | $47 |
| Ct scan of chest with contrast | 54 | $2,415 | $45 |
| Radioactive drug therapy through a vein | 22 | $2,207 | $85 |
| Nuclear medicine study of lymphatic system | 21 | $1,093 | $52 |
| Ct scan of abdomen and pelvis before and after contrast | 13 | $1,079 | $83 |
| Calculation of radiation therapy dose | 27 | $929 | $31 |
| Nuclear medicine study of bone and/or joint whole body | 29 | $903 | $31 |
| Dxa bone density measurement of hip, pelvis, spine | 68 | $741 | $11 |
| Nuclear medicine study of stomach to assess emptying | 17 | $560 | $33 |
| 3d radiographic procedure with computerized image postprocessing | 15 | $539 | $36 |
| Nuclear medicine study, 1 area | 12 | $343 | $29 |
2021: 30 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 157 | $135,414 | $821 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 228 | $25,238 | $107 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 95 | $24,816 | $256 |
| Nuclear medicine study whole body with ct scan | 51 | $21,342 | $410 |
| Nuclear medicine study of bone and/or joint whole body | 63 | $15,546 | $247 |
| Nuclear medicine study whole body with ct scan | 67 | $7,641 | $109 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 86 | $6,206 | $71 |
| Mri scan of abdomen before and after contrast | 15 | $5,230 | $349 |
| Ct scan of abdomen and pelvis before and after contrast | 17 | $5,212 | $307 |
| Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 25 | $5,020 | $201 |
| Nuclear medicine study of stomach to assess emptying | 17 | $4,322 | $254 |
| Dxa bone density measurement of hip, pelvis, spine | 312 | $3,516 | $11 |
| Nuclear medicine study of lymphatic system | 16 | $3,194 | $200 |
| Screening mammography | 20 | $3,130 | $157 |
| Nuclear medicine study of liver and bile duct system | 11 | $2,725 | $248 |
| Complete ultrasound scan of abdomen | 31 | $2,534 | $82 |
| Nuclear medicine study, spect imaging with concurrent ct scan, 1 area or single acquisition, single day imaging | 38 | $2,520 | $65 |
| Ct scan of abdomen and pelvis with contrast | 14 | $2,225 | $159 |
| Ct scan of abdomen and pelvis without contrast | 13 | $1,494 | $115 |
| Ultrasound scan of head and neck soft tissue | 14 | $1,289 | $92 |
| Screening 3d breast mammography | 19 | $1,198 | $63 |
| Nuclear medicine study of bone and/or joint whole body | 26 | $1,008 | $37 |
| Dxa bone density measurement of hip, pelvis, spine | 78 | $867 | $11 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 67 | $809 | $12 |
| Nuclear medicine study of lymphatic system | 13 | $690 | $53 |
| Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 11 | $565 | $51 |
| Nuclear medicine study of stomach to assess emptying | 14 | $499 | $36 |
| Limited ultrasound scan behind abdominal cavity | 11 | $471 | $43 |
| Injection, gadoterate meglumine, 0.1 ml | 17 | $388 | $0 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 23 | $174 | $0 |
2020: 25 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 224 | $325,169 | $1,384 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 235 | $49,051 | $200 |
| Nuclear medicine study whole body with ct scan | 23 | $32,134 | $1,397 |
| Ct scan of abdomen and pelvis before and after contrast | 76 | $24,546 | $319 |
| Nuclear medicine study of bone and/or joint whole body | 52 | $13,644 | $262 |
| Mri scan of abdomen before and after contrast | 31 | $10,815 | $338 |
| Ct scan of abdomen and pelvis with contrast | 37 | $10,603 | $279 |
| Ct scan of abdomen and pelvis without contrast | 47 | $7,916 | $168 |
| Complete ultrasound scan of abdomen | 60 | $6,157 | $103 |
| Ultrasound scan of head and neck soft tissue | 35 | $3,310 | $95 |
| Mri scan of pelvis before and after contrast | 12 | $3,220 | $268 |
| Nuclear medicine study of stomach to assess emptying | 11 | $3,131 | $285 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 25 | $2,496 | $96 |
| Ultrasound study of arm or leg veins with compression and maneuvers | 14 | $2,428 | $173 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 20 | $2,372 | $113 |
| Complete ultrasound scan of pelvis | 23 | $2,176 | $95 |
| Ct scan of chest with contrast | 19 | $2,095 | $110 |
| Ct scan of chest before and after contrast | 14 | $1,752 | $117 |
| Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 14 | $1,401 | $100 |
| Limited ultrasound scan of abdomen | 14 | $1,171 | $84 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 124 | $933 | $0 |
| Limited ultrasound scan behind abdominal cavity | 17 | $868 | $51 |
| Injection, gadoterate meglumine, 0.1 ml | 35 | $866 | $0 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 60 | $720 | $12 |
| X-ray of abdomen, 1 view | 12 | $280 | $23 |
2019: 22 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 232 | $315,218 | $1,319 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 266 | $54,232 | $197 |
| Nuclear medicine study whole body with ct scan | 38 | $50,752 | $1,269 |
| Ct scan of abdomen and pelvis before and after contrast | 53 | $15,412 | $291 |
| Nuclear medicine study of bone and/or joint whole body | 46 | $12,632 | $269 |
| Mri scan of abdomen before and after contrast | 34 | $11,263 | $331 |
| Complete ultrasound scan of abdomen | 79 | $8,358 | $106 |
| Ct scan of abdomen and pelvis without contrast | 37 | $6,121 | $165 |
| Ct scan of abdomen and pelvis with contrast | 22 | $5,936 | $270 |
| Ultrasound scan of head and neck soft tissue | 43 | $4,374 | $99 |
| Complete ultrasound scan of pelvis | 43 | $4,133 | $96 |
| Mri scan of abdomen without contrast | 20 | $4,034 | $202 |
| Mri scan of pelvis before and after contrast | 14 | $3,598 | $257 |
| Complete ultrasound scan behind abdominal cavity | 35 | $3,530 | $98 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 33 | $3,491 | $106 |
| Ct scan of abdomen before and after contrast | 12 | $2,603 | $217 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 17 | $1,925 | $113 |
| Injection, gadoterate meglumine, 0.1 ml | 36 | $1,036 | $0 |
| X-ray of chest, 2 views | 33 | $880 | $25 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 89 | $734 | $0 |
| Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 13 | $596 | $46 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 47 | $556 | $12 |
2018: 24 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 129 | $142,275 | $1,103 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 115 | $21,577 | $188 |
| Nuclear medicine study whole body with ct scan | 14 | $15,642 | $1,117 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 95 | $8,937 | $93 |
| Nuclear medicine study of bone and/or joint whole body | 30 | $5,936 | $198 |
| Ct scan of abdomen and pelvis before and after contrast | 19 | $5,527 | $291 |
| Mri scan of abdomen before and after contrast | 16 | $4,463 | $279 |
| Ct scan of abdomen and pelvis without contrast | 19 | $3,271 | $172 |
| Mri scan of abdomen without contrast | 12 | $2,771 | $231 |
| Mri scan of abdomen before and after contrast | 25 | $2,133 | $85 |
| Complete ultrasound scan of abdomen | 18 | $2,012 | $112 |
| Nuclear medicine study whole body with ct scan | 17 | $1,617 | $95 |
| Nuclear medicine study of bone and/or joint whole body | 44 | $1,523 | $34 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 12 | $1,343 | $112 |
| Mri scan of pelvis before and after contrast | 15 | $1,244 | $83 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 21 | $1,196 | $57 |
| Nuclear medicine study of lymphatic system | 15 | $707 | $47 |
| Injection, gadoterate meglumine, 0.1 ml | 14 | $459 | $0 |
| Complete ultrasound scan behind abdominal cavity | 13 | $372 | $29 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 22 | $332 | $15 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 34 | $327 | $0 |
| Limited ultrasound scan of abdomen | 13 | $297 | $23 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 23 | $267 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 22 | $210 | $10 |
2017: 26 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 96 | $44,656 | $451 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 288 | $28,579 | $95 |
| Nuclear medicine study whole body with ct scan | 18 | $10,077 | $530 |
| Nuclear medicine study whole body with ct scan | 55 | $5,566 | $98 |
| Mri scan of abdomen before and after contrast | 44 | $4,053 | $92 |
| Nuclear medicine study of bone and/or joint whole body | 94 | $3,463 | $35 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 52 | $3,241 | $62 |
| Mri scan of pelvis before and after contrast | 27 | $2,570 | $95 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 19 | $1,850 | $93 |
| Nuclear medicine study of lung ventilation and circulation | 29 | $1,248 | $43 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 19 | $1,198 | $63 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 64 | $1,154 | $18 |
| Complete ultrasound scan behind abdominal cavity | 32 | $953 | $30 |
| Nuclear medicine study of parathyroid with spect and ct scan | 14 | $898 | $64 |
| Limited ultrasound scan of abdomen | 36 | $811 | $23 |
| Nuclear medicine study of lymphatic system | 16 | $793 | $50 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 64 | $779 | $12 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 12 | $775 | $65 |
| Nuclear medicine study of heart muscle with metabolic evaluation | 12 | $709 | $59 |
| Nuclear medicine study of bone and/or joint whole body | 18 | $634 | $35 |
| Complete ultrasound scan of abdomen | 18 | $607 | $34 |
| Ultrasound scan of head and neck soft tissue | 25 | $567 | $23 |
| Ultrasound scan of transplanted kidney | 17 | $538 | $32 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 14 | $457 | $33 |
| Nuclear medicine study of stomach to assess emptying | 13 | $425 | $33 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 19 | $235 | $12 |
2016: 24 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 373 | $39,262 | $97 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 75 | $18,123 | $227 |
| Nuclear medicine study whole body with ct scan | 65 | $6,854 | $98 |
| Nuclear medicine study of bone and/or joint whole body | 100 | $3,509 | $34 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 54 | $3,385 | $63 |
| Ct scan of abdomen and pelvis with contrast | 39 | $2,834 | $73 |
| Nuclear medicine study whole body with ct scan | 15 | $1,912 | $101 |
| Nuclear medicine study of lung ventilation and circulation | 39 | $1,690 | $43 |
| Nuclear medicine study of lymphatic system | 29 | $1,432 | $49 |
| Mri scan of abdomen before and after contrast | 19 | $1,425 | $75 |
| Mri scan of pelvis before and after contrast | 14 | $1,306 | $93 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 54 | $979 | $18 |
| Nuclear medicine study of bone and/or joint whole body | 22 | $747 | $34 |
| Nuclear medicine study of parathyroid with spect and ct scan | 11 | $703 | $64 |
| Nuclear medicine study of stomach to assess emptying | 23 | $703 | $31 |
| Complete ultrasound scan behind abdominal cavity | 24 | $702 | $29 |
| Complete ultrasound scan of abdomen | 22 | $695 | $32 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 54 | $636 | $12 |
| Ultrasound scan of head and neck soft tissue | 30 | $612 | $20 |
| Nuclear medicine study of brain with metabolic evaluation | 11 | $538 | $49 |
| Ultrasound scan of transplanted kidney | 15 | $524 | $31 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 17 | $505 | $30 |
| Limited ultrasound scan of abdomen | 25 | $494 | $20 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 11 | $208 | $19 |
2015: 23 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 296 | $31,396 | $102 |
| Nuclear medicine study whole body with ct scan | 55 | $5,819 | $104 |
| Ct scan of abdomen and pelvis with contrast | 54 | $4,074 | $75 |
| Nuclear medicine study of bone and/or joint whole body | 87 | $3,104 | $35 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 43 | $2,738 | $64 |
| Ct scan of abdomen and pelvis without contrast | 26 | $1,910 | $71 |
| Nuclear medicine study of lung ventilation and circulation | 36 | $1,572 | $44 |
| Ct scan of abdomen and pelvis before and after contrast | 15 | $1,355 | $85 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 12 | $1,138 | $95 |
| Complete ultrasound scan behind abdominal cavity | 37 | $1,099 | $29 |
| Ultrasound scan of head and neck soft tissue | 44 | $974 | $22 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 47 | $814 | $17 |
| Nuclear medicine study of lymphatic system | 15 | $737 | $49 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 14 | $695 | $50 |
| Nuclear medicine study of parathyroid with spect and ct scan | 11 | $673 | $61 |
| Complete ultrasound scan of abdomen | 21 | $651 | $31 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 53 | $605 | $11 |
| Limited ultrasound scan of abdomen | 23 | $543 | $24 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 16 | $503 | $31 |
| Nuclear medicine study of stomach to assess emptying | 15 | $461 | $31 |
| Ultrasound scan of transplanted kidney | 15 | $442 | $29 |
| Complete ultrasound scan of pelvis | 17 | $427 | $25 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 14 | $365 | $26 |
2014: 23 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 318 | $35,179 | $101 |
| Nuclear medicine study whole body with ct scan | 40 | $4,373 | $102 |
| Nuclear medicine study of bone and/or joint whole body | 95 | $3,278 | $34 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 50 | $3,152 | $63 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 25 | $2,804 | $100 |
| Nuclear medicine study of lung ventilation and circulation | 36 | $1,415 | $39 |
| Complete ultrasound scan behind abdominal cavity | 45 | $1,360 | $29 |
| Ultrasound scan of head and neck soft tissue | 56 | $1,277 | $23 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 28 | $1,270 | $45 |
| Ct scan of abdomen and pelvis with contrast | 15 | $1,068 | $71 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress | 17 | $1,046 | $62 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 58 | $977 | $17 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 12 | $863 | $43 |
| Complete ultrasound scan of abdomen | 30 | $861 | $29 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 71 | $811 | $11 |
| Nuclear medicine study of stomach to assess emptying | 19 | $626 | $33 |
| Nuclear medicine study of lymphatic system | 12 | $591 | $49 |
| Ultrasound scan of uterus, ovaries, tubes, cervix and pelvic area through vagina | 23 | $582 | $25 |
| Complete ultrasound scan of pelvis | 22 | $541 | $25 |
| Limited ultrasound scan of abdomen | 23 | $507 | $22 |
| Ultrasound scan of transplanted kidney | 13 | $477 | $32 |
| Nuclear medicine study of whole body for thyroid cancer | 11 | $412 | $34 |
| Ultrasound study of one arm or leg veins with compression and maneuvers | 12 | $247 | $19 |
2013: 18 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 253 | $25,303 | $96 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 55 | $3,336 | $61 |
| Nuclear medicine study of bone and/or joint whole body | 76 | $2,539 | $33 |
| Nuclear medicine study whole body with ct scan | 19 | $1,891 | $100 |
| Ct scan of abdomen and pelvis with contrast | 25 | $1,678 | $67 |
| Nuclear medicine study of lung ventilation and circulation | 36 | $1,565 | $43 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 16 | $1,071 | $41 |
| Ultrasound of abdomen and pelvis artery and vein blood flow | 22 | $1,064 | $48 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 60 | $1,020 | $17 |
| Ultrasound scan of head and neck soft tissue | 45 | $986 | $22 |
| Complete ultrasound scan behind abdominal cavity | 33 | $890 | $27 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 71 | $790 | $11 |
| Nuclear medicine study of stomach to assess emptying | 24 | $741 | $31 |
| Complete ultrasound scan of abdomen | 23 | $711 | $31 |
| Limited ultrasound scan of abdomen | 21 | $476 | $23 |
| Nuclear medicine study of lung ventilation and circulation and blood flow to lung | 12 | $410 | $34 |
| Ultrasound scan of transplanted kidney | 11 | $329 | $30 |
| Nuclear medicine study of thyroid and thyroid function | 11 | $217 | $20 |
Medicaid work
$35,762 in 2024
Medicaid paid $35,762 for 179 billed services this clinician did in 2024, up to 29 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 145 | $35,532 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 34 | $230 |
| 2024 | 179 | 2 | 29 | $35,762 |
| 2023 | 129 | 2 | 26 | $18,544 |
| 2022 | 167 | 1 | 24 | $26,546 |
| 2021 | 429 | 10 | 33 | $17,347 |
| 2020 | 567 | 5 | 27 | $29,951 |
| 2019 | 772 | 8 | 29 | $20,859 |
| 2018 | 54 | 3 | 14 | $6,891 |
See the largest Medicaid services in earlier years
2023
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 90 | $18,385 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 39 | $159 |
2022
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 167 | $26,546 |
2021
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 114 | $16,537 |
| BONE IMAGING WHOLE BODY | 14 | $279 |
| DXA BONE DENSITY STUDY 1/> SITES AXIAL SKEL | 49 | $231 |
| Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 64 | $129 |
| Ultrasound, abdominal, real time with image documentation; complete | 49 | $83 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 27 | $50 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 15 | $37 |
| Ultrasound by transvaginal approach | 53 | $0 |
| SCREENING DIGITAL BREAST TOMOSYNTHESIS BI | 22 | $0 |
| Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (CAD) when performed | 22 | $0 |
2020
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 154 | $25,434 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 175 | $3,717 |
| Ultrasound, abdominal, real time with image documentation; complete | 69 | $543 |
| Ultrasound by transvaginal approach | 71 | $189 |
| Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 98 | $68 |
2019
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 106 | $19,719 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 90 | $510 |
| Ultrasound, abdominal, real time with image documentation; complete | 131 | $254 |
| Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 210 | $244 |
| Ultrasound by transvaginal approach | 168 | $122 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 26 | $11 |
| Radiologic examination, chest; 2 views | 14 | $0 |
| Ultrasound, soft tissues of head and neck (eg, thyroid, parathyroid, parotid), real time with image documentation | 27 | $0 |
2018
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 26 | $6,174 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 14 | $716 |
| Ultrasound, abdominal, real time with image documentation; complete | 14 | $0 |
Money from drug and device companies
$109 in 2025
A payment is not proof that care is biased.
| Ge Healthcare | None | $70 | 1 payment
|
| Telix Pharmaceuticals | None | $38 | 1 payment
|
See all 2 published payments
| Telix Pharmaceuticals | Meals · 2025-01-31 | None | $38 |
| Ge Healthcare | Meals · 2025-01-31 | None | $70 |
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177lu]Lu-Evs459 in Patients With Ovarian and Lung Cancers · 2024 | Their institution | $14,830 |
| Novartis Pharmaceuticals Corporation · A Phase I, Open-Label, Multi-Center Study To Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177lu]Lu-Evs459 in Patients With Ovarian and Lung Cancers · 2025 | Their institution | $14,526 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1669521191
- Licence
- CA C151875, PA MD444163, PA MT188957California C151875: Current · expires 2027-04-30
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2085N0904X (2085N0904X); Federal specialty code 207U00000X (207U00000X); Federal specialty code 2085B0100X (2085B0100X); Diagnostic radiology (2085R0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-10
- NPI last updated
- 2024-04-07
- NPI record certified
- 2024-04-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 3400 Spruce Street, Philadelphia, PA, 19104